LifeTime and improving European healthcare through cell-based interceptive medicine

Rajewsky, Nicolaus; Bertero, Michela G.; Marti-Renom, Marc A.; LifeTime Community

doi:http://dx.doi.org/10.1038/s41586-020-2715-9

LifeTime and improving European healthcare through cell-based interceptive medicine

License

Citation

Rajewsky N, Almouzni G, Gorski SA, Aerts S, Amit I, Bertero MG et al. LifeTime and improving European healthcare through cell-based interceptive medicine. Nature. 2020 Sep 7; 587:377-86. DOI: 10.1038/s41586-020-2715-9

Abstract

LifeTime aims to track, understand and target human cells during the onset and progression of complex diseases and their response to therapy at single-cell resolution. This mission will be implemented through the development and integration of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during progression from health to disease. Analysis of such large molecular and clinical datasets will discover molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. Timely detection and interception of disease embedded in an ethical and patient-centered vision will be achieved through interactions across academia, hospitals, patient-associations, health data management systems and industry. Applying this strategy to key medical challenges in cancer, neurological, infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade.